

**Attachment A
CCHRI 2009
Required HEDIS Measures**

Measure	Numerator	Description	Product Line
Adult BMI Assessment			Commercial/Medicare
Annual Monitoring for Patients on Persistent Medications	Numerator 1	Total	Commercial/Medicare/PPO
Annual Monitoring for Patients on Persistent Medications	Numerator 2	ACE Inhibitors or ARBs	Commercial/Medicare/PPO
Annual Monitoring for Patients on Persistent Medications	Numerator 3	Digoxin	Commercial/Medicare/PPO
Annual Monitoring for Patients on Persistent Medications	Numerator 4	Diuretics	Commercial/Medicare/PPO
Annual Monitoring for Patients on Persistent Medications	Numerator 5	Anticonvulsants	Commercial/Medicare/PPO
Antidepressant Medication Management	Numerator 2	Effective Acute Phase Treatment	Commercial/Medicare/PPO
Antidepressant Medication Management	Numerator 3	Effective Continuation Phase Treatment	Commercial/Medicare/PPO
Appropriate Testing for Children with Pharyngitis			Commercial/PPO
Appropriate Treatment for Children with Upper Respiratory Infection			Commercial/PPO
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis			Commercial/PPO
Breast Cancer Screening	Numerator 1	Total	Commercial/Medicare/PPO
Call Abandonment			Commercial/Medicare/PPO
Call Answer Timeliness			Commercial/Medicare/PPO
Care for Older Adults	Numerator 1	Advance Care Planning	Medicare SNP
Care for Older Adults	Numerator 2	Medication Review	Medicare SNP
Care for Older Adults	Numerator 3	Functional Status Assessment	Medicare SNP
Care for Older Adults	Numerator 4	Pain Screening	Medicare SNP
Cervical Cancer Screening			Commercial/PPO
Childhood Immunizations	Numerator 2	Combo 2	Commercial
Childhood Immunizations	Numerator 3	MMR	Commercial
Childhood Immunizations	Numerator 4	HiB	Commercial
Childhood Immunizations	Numerator 5	VZV	Commercial
Childhood Immunizations	Numerator 6	HepB	Commercial
Childhood Immunizations	Numerator 7	DTP	Commercial

**Attachment A
CCHRI 2009
Required HEDIS Measures**

Measure	Numerator	Description	Product Line
Childhood Immunizations	Numerator 8	IPV	Commercial
Childhood Immunizations	Numerator 9	Pneumococcal Conjugate	Commercial
Childhood Immunizations	Numerator 10	Combo 3	Commercial
Chlamydia Screening in Women	Numerator 1	Age 16-20	Commercial/PPO
Chlamydia Screening in Women	Numerator 2	Age 21-25	Commercial/PPO
Chlamydia Screening in Women	Numerator 3	Total	Commercial/PPO
Cholesterol Management for Patients with Cardiovascular Conditions	Numerator 1	LDL-C Screening	Commercial/Medicare/PPO
Cholesterol Management for Patients with Cardiovascular Conditions	Numerator 3	LDL-C Level of <100 mg/dL	Commercial/Medicare
Colorectal Cancer Screening			Commercial/Medicare
Comprehensive Diabetes Care	Numerator 1	HbA1c Test	Commercial/Medicare/PPO
Comprehensive Diabetes Care	Numerator 2	HbA1c Poor Control (>9.0 percent)	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 3	Retinal Exam	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 4	LDL-C Screening	Commercial/Medicare/PPO
Comprehensive Diabetes Care	Numerator 6	LDL-C Level of <100 mg/dL	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 7	Medical Attention for Nephropathy	Commercial/Medicare/PPO
Comprehensive Diabetes Care	Numerator 8	Blood Pressure Control (<130/80)	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 9	Blood Pressure Control (<140/90)	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 10	HbA1c Control (<7.0 percent)	Commercial/Medicare
Comprehensive Diabetes Care	Numerator 11	HbA1c Control (<8.0 percent)	Commercial/Medicare
Controlling High Blood Pressure			Commercial/Medicare
Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis			Commercial/Medicare/PPO
Flu Shots for Adults Ages 50 – 64			Commercial (survey)
Follow-up After Hospitalization for Mental Illness	Numerator 1	Follow-up within 30 days of hospital discharge	Commercial/Medicare/PPO
Follow-up After Hospitalization for Mental Illness	Numerator 2	Follow-up within 7 days of hospital discharge	Commercial/Medicare/PPO
Follow-up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder	Numerator 1	Initiation Phase	Commercial/PPO
Follow-up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder	Numerator 2	Continuation and Maintenance (C&M) Phase	Commercial/PPO

**Attachment A
CCHRI 2009
Required HEDIS Measures**

Measure	Numerator	Description	Product Line
Glaucoma Screening in Older Adults			Medicare
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 1a	Initiation of AOD Treatment - Total	Commercial/Medicare/PPO
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 1b	Initiation of AOD Treatment - Age 13-17	Commercial/Medicare/PPO
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 1c	Initiation of AOD Treatment - Age 18+	Commercial/Medicare/PPO
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 2a	Engagement of AOD Treatment - Total	Commercial/Medicare/PPO
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 2b	Engagement of AOD Treatment - Age 13-17	Commercial/Medicare/PPO
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	Numerator 2c	Engagement of AOD Treatment - Age 18+	Commercial/Medicare/PPO
Medical Assistance with Smoking Cessation	Numerator 1	Advising Smokers to Quit	Commercial/PPO (survey)
Medical Assistance with Smoking Cessation	Numerator 2	Discussing Cessation Medications	Commercial/PPO (survey)
Medical Assistance with Smoking Cessation	Numerator 3	Discussing Cessation Strategies	Commercial/PPO (survey)
Medication Reconciliation Post-Discharge			Medicare SNP
Osteoporosis Management in Women Who had a Fracture			Medicare
Persistence of Beta-Blocker Treatment After a Heart Attack			Commercial/Medicare/PPO
Pharmacotherapy Management for COPD Exacerbation			Commercial/Medicare
Potentially Harmful Drug-Disease Interactions in the Elderly	Numerator 1	Total	Medicare
Potentially Harmful Drug-Disease Interactions in the Elderly	Numerator 2	Falls + Tricyclic Antidepressants or Antipsychotics or Sleep Agents	Medicare
Potentially Harmful Drug-Disease Interactions in the Elderly	Numerator 3	Dementia + Tricyclic Antidepressants or Anticholinergic Agents	Medicare
Potentially Harmful Drug-Disease Interactions in the Elderly	Numerator 4	Chronic Renal Failure + Nonaspirin NSAIDS or Cox-2 Selective NSAIDS	Medicare
Prenatal and Postpartum Care	Numerator 1	Timely Initiation of Prenatal Care	Commercial
Prenatal and Postpartum Care	Numerator 2	Postpartum Care	Commercial
Use of Appropriate Medications for People with Asthma	Numerator 1	Age 5-9	Commercial/PPO
Use of Appropriate Medications for People with Asthma	Numerator 2	Age 10-17	Commercial/PPO
Use of Appropriate Medications for People with Asthma	Numerator 3	Age 18-56	Commercial/PPO
Use of Appropriate Medications for People with Asthma	Numerator 4	Total	Commercial/PPO
Use of High-Risk Medications in the Elderly	Numerator 1	One Prescription	Medicare
Use of High-Risk Medications in the Elderly	Numerator 2	Two or More Prescriptions	Medicare

**Attachment A
CCHRI 2009
Required HEDIS Measures**

Measure	Numerator	Description	Product Line
Use of Imaging Studies for Low Back Pain			Commercial/PPO
Use of Spirometry Testing in the Assessment and Diagnosis of COPD			Commercial/Medicare
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents			Commercial

The actual set of measures reported either publicly or internal only is determined by the Reporting Committee (approved by the Executive Committee), usually in May/June of the Reporting Year. The above is a list of the measures that are likely to be reported.